Depatuxizumab Mafodotin

Depatuxizumab Mafodotin (ABT-414) is an antibody drug conjugate (ADC) targeting EGFR that is being investigated to treat glioblastoma (GBM).

Type of Molecule

Biologic

Target

EGFR

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Glioblastoma (GBM) n/a
Phase 3
Pediatric Brain Tumors n/a
Phase 1